ATP Citrate Lyase
ATP Citrate Lyase inhibitors are compounds that target the enzyme ATP citrate lyase, which plays a key role in the biosynthesis of fatty acids and cholesterol by converting citrate to acetyl-CoA. In the context of neuroscience, these inhibitors are of interest due to their potential effects on lipid metabolism in the brain, which is crucial for maintaining neuronal function and integrity. Inhibiting ATP citrate lyase can have implications for neurodegenerative diseases, where lipid metabolism is often dysregulated. At CymitQuimica, we offer ATP citrate lyase inhibitors to support your research in brain metabolism, neurodegeneration, and therapeutic development.
Found 18 products for "ATP Citrate Lyase".
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Citric acid trilithium salt tetrahydrate
CAS:Citric acid trilithium salt tetrahydrate (Lithium citrate tribasic tetrahydrate) , the active component of Lithium, is a medicine used in the therapy ofFormula:C6H13Li3O11Purity:99.88%Color and Shape:White SolidMolecular weight:281.98Hydroxycitric acid tripotassium hydrate
CAS:Hydroxycitric acid tripotassium hydrate (Potassium citrate monohydrate) effectively inhibits HIF, has antioxidation, anti-inflammation, and anti-tumor effects.Formula:C6H7K3O8Purity:99.85%Color and Shape:White Solid CrystallineMolecular weight:324.41(-)-Hydroxycitric acid lactone
CAS:(-)-Hydroxycitric acid lactone (Garcinia lactone) is an anti-obesity agent.(-)-Hydroxycitric acid lactone was a potent inhibitor of ATP citrate lyase, whichFormula:C6H6O7Purity:99.85% - 99.91%Color and Shape:White SolidMolecular weight:190.11(-)-Hydroxycitric acid
CAS:(-)-Hydroxycitric acid from Garcinia cambogia rinds inhibits ATP citrate lyase, reducing fat synthesis and aiding weight loss.Formula:C6H8O8Purity:99.18% - 99.90%Color and Shape:SolidMolecular weight:208.12Forrestiacids K
CAS:Forrestiacid K, a terpenoid derived from Pseudotsuga forrestii, functions as an inhibitor of ATP-citrate lyase (ACL) [1].Formula:C50H74O6Purity:98%Color and Shape:SolidMolecular weight:771.12Forrestiacids J
CAS:Forrestiacid J is an inhibitor of ATP-citrate lyase (ACL), exhibiting an IC50 value of 2.6 μM [1].Formula:C50H74O6Purity:98%Color and Shape:SolidMolecular weight:771.12ATP citrate lyase/ACLY Protein, Human, Recombinant (His)
ATP citrate lyase, also known as Acly or Acl, is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues.Purity:96%Color and Shape:Transparent SolutionMolecular weight:123 kDa (predicted); 110 kDa (reducing conditions)Anti-ATP citrate lyase/ACLY Antibody (9F685)
Anti-ATP citrate lyase/ACLY Antibody (9F685) is an antibody targeting ATP citrate lyase/ACLY. Anti-ATP citrate lyase/ACLY Antibody (9F685) can be used in ELISA, WB, IF, FCM.Color and Shape:Odour LiquidSB 204990
CAS:SB 204990 is a lactone prodrug of SB-201076, a potent and specific ATP citrate lyase inhibitor.Cost-effective and quality-assured.Formula:C18H22Cl2O5Purity:96.32% - 99.88%Color and Shape:SolidMolecular weight:389.27BMS-303141
CAS:BMS-303141 is a potent ATP-citrate lyase (ACL) inhibitor (IC50: 0.13 uM, human recombinant ACL).Formula:C19H15Cl2NO4SPurity:98% - 99.47%Color and Shape:White SolidMolecular weight:424.3Ref: TM-T2337
1mg34.00€2mg44.00€5mg63.00€1mL*10mM (DMSO)65.00€10mg82.00€25mg133.00€50mg254.00€100mg371.00€2-Furoic acid
CAS:2-Furoic acid: oral cathepsin K inhibitor, potential for treating osteoporosis and antibacterial.Formula:C5H4O3Purity:99.53% - 99.65%Color and Shape:White SolidMolecular weight:112.08NDI-091143
CAS:NDI-091143 is a potent and high-affinity human ATP-citrate lyase (ACLY) inhibitor with an IC50 of 2.1 nM (ADP-Glo assay),indirectly disrupting citrate bindingFormula:C20H14ClF2NO5SPurity:97.03% - ≥95%Color and Shape:SolidMolecular weight:453.84Bempedoic acid
CAS:Bempedoic acid (ETC1002) is an orally available, once-daily LDL-C lowering small molecule designed to lower elevated levels of LDL-C.Formula:C19H36O5Purity:99.85% - 99.94%Color and Shape:White SolidMolecular weight:344.49Ref: TM-T3625
2mg34.00€5mg50.00€1mL*10mM (DMSO)52.00€10mg70.00€25mg118.00€50mg207.00€100mg333.00€500mg797.00€EVT0185
CAS:EVT0185 is an orally active ATP citrate lyase (ACLY) inhibitor. In the liver, it is converted by SLC27A2 into a CoA thioester, which interacts with the CoA binding site of ACLY. EVT0185-CoA inhibits ACLY activity with an IC50 of 2.5 μM. It mimics the immune and antitumor effects seen with ACLY gene deletion. Additionally, EVT0185 elevates levels of tumor-infiltrating B cells and the chemokine CXCL13. It is applicable in cancer research, including hepatocellular carcinoma (HCC).Formula:C22H34O4Color and Shape:SolidMolecular weight:362.50MEDICA16
CAS:MEDICA16: GPR40 agonist, GPR120 partial agonist, ATP-citrate lyase inhibitor, lowers TG, boosts insulin sensitivity in muscle.Formula:C20H38O4Purity:99.62% - 99.87%Color and Shape:SolidMolecular weight:342.51ACLY-IN-1
CAS:ACLY-IN-1 (compound 55) is a potent ACLY inhibitor with an IC50 of 8.3 nM, and it can be utilized in hyperlipidemia research.Formula:C20H12BrClF2N2O4SColor and Shape:SolidMolecular weight:529.74ACLY Inhibitor 7
CAS:ACLY Inhibitor 7 is a potent, selective hACLY inhibitor (IC50<1 nM) for metabolic disease and oncology research.Formula:C21H14ClF2NO6SPurity:99.74%Color and Shape:SolidMolecular weight:481.85BGT-002
CAS:BGT-002 (326E) is an orally active dual ACLY inhibitor and PPARα agonist. It reduces lipogenesis by inhibiting synthesis and promoting excretion. BGT-002 has demonstrated efficacy in vivo for improving metabolic dysfunction-associated steatohepatitis (MASH) and alleviating hyperlipidemia. It is applicable for research on hypercholesterolemia and MASH.Formula:C19H34O4Molecular weight:326.48
